The next generation of the industry’s leading, clinically validated and scalable electroporation technology for complex cellular engineering.

  • Rapidly transfect from 75 thousand to 20 billion cells
  • 21CFR Part 11 enabled software
  • Established regulatory path supported by FDA Master File
  • Closed, cGMP-compliant, ISO-certified and CE-marked
  • MaxCyte’s proprietary Flow Electroporation™ Technology

Resources3D VIEWQuote

Download GTx